Therapeutic efficasy of artemether-lumefantrine

Full metadata record
DC FieldValueLanguage
dc.contributor.authorHaque, Rashidul-
dc.contributor.authorThriemer, Kamala-
dc.date.accessioned2007-11-25T04:20:14Z-
dc.date.available2007-11-25T04:20:14Z-
dc.date.issued2007-11-25T04:20:14Z-
dc.identifier.urihttp://hdl.handle.net/123456789/390-
dc.descriptionShort reporten
dc.description.abstractBangladesh faces increasing levels of chloroquine resistance, and drug sensitivity to sulfadoxinepyremethamine is already compromised. Therefore, the Ministry of Health recently changed the national treatment guidelines to artemisinin-based combination therapies. The purpose of this study was to determine the baseline therapeutic efficacy of artemether-lumefantrine used as a six-dose regimen for the treatment of uncomplicated Plasmodium falciparum malaria. Sixty-seven patients were enrolled in the study; the cure rate in a 42-day follow-up after an adjustment by polymerase chain reaction was 94.3%. The treatment led to rapid fever (mean ± SD  25.82 ± 12.14 hours) and parasite (30.36 ± 19.43 hours) clearance. These data suggest that artemether-lumefantrine is a highly efficacious and well-tolerated treatment for uncomplicated P. falciparum malaria in Bangladesh.en
dc.description.sponsorshipThe study was supported by the United States Department of Defense Global Emerging Infections System program and the Austrian Science Fund (project no. 15754-B02).en
dc.format.extent54106 bytes-
dc.format.mimetypeapplication/pdf-
dc.language.isoen_USen
dc.subjectPlasmodium Falciparumen
dc.titleTherapeutic efficasy of artemether-lumefantrineen
dc.typeArticleen
Appears in Collections:A. Original papers

Files in This Item:
File Description SizeFormat 
Haque R_Am J Trop Med Hyg_Jan07.pdf52.84 kBAdobe PDFView/Open    Request a copy


This item is protected by original copyright